ProfileJobs

Endologix

Healthbiotechdrug development

Endologix, Inc. is singularly focused on providing innovative, minimally invasive technologies for aortic disorders. The Company's product offering includes a variety of endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Designed around key issues with challenging anatomies, difficult access, and aneurysm sealing, Endologix products have been clinically proven in delivering positive patient outcomes. 

Revenue(Q1, 2017)
$42.6 M
Market capitalization(2017-08-17)
$354.6 M
Company Growth (employees)
Type
Public
HQ
Irvine, US
Founded
1992
Size (employees)
782 (est)
Website
endologix.com
Endologix was founded in 1992 and is headquartered in Irvine, US

Endologix Office Locations

Endologix has offices in Irvine and Rosmalen
Irvine, US (HQ)
2 Musick
Rosmalen, NL
40 Burgemeester Burgerslaan

Endologix Data and Metrics

Endologix Financial Metrics

Endologix's revenue was reported to be $42.6 m in Q1, 2017
USD

Revenue (Q1, 2017)

42.6 m

Gross profit (Q1, 2017)

28.6 m

Gross profit margin (Q1, 2017), %

67%

Net income (Q1, 2017)

(21.3 m)

EBIT (Q1, 2017)

(15.7 m)

Market capitalization (17-Aug-2017)

354.6 m

Cash (31-Mar-2017)

15.5 m
Endologix's current market capitalization is $354.6 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

132.3 m147.6 m153.6 m192.9 m

Revenue growth, %

12%4%26%

Cost of goods sold

41.8 m51.8 m69.1 m

Gross profit

99.5 m105.8 m101.8 m123.8 m

Gross profit Margin, %

75%72%66%64%

R&D expense

32.3 m

General and administrative expense

41 m

Operating expense total

109.9 m134.9 m154.7 m218.9 m

EBIT

(10.4 m)(29.1 m)(52.9 m)(95.1 m)

EBIT margin, %

(8%)(20%)(34%)(49%)

Interest expense

321 k5.7 m7.5 m15.8 m

Interest income

50 k245 k175 k228 k

Income tax expense

10 k62 k9.3 m(498 k)

Net Income

(16.1 m)(32.4 m)(50.4 m)(154.7 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

38.3 m37.2 m36.7 m39.5 m38.2 m42.4 m51 m52.1 m42.6 m

Cost of goods sold

9.8 m13.6 m9.8 m15.3 m11.2 m14.4 m21.5 m15.2 m14 m

Gross profit

28.5 m23.6 m26.9 m24.1 m27 m27.9 m29.5 m36.9 m28.6 m

Gross profit Margin, %

74%63%73%61%71%66%58%71%67%

R&D expense

4.5 m5.3 m6.2 m6 m5.5 m7.8 m7.7 m8.2 m5.5 m

General and administrative expense

5.9 m6.3 m7.3 m6.9 m7.3 m9.9 m10.2 m9.7 m8.9 m

Operating expense total

10.4 m11.6 m13.5 m12.8 m12.8 m17.8 m17.9 m18 m14.4 m

EBIT

(3.8 m)(8.9 m)(9.7 m)(12.2 m)(9.3 m)(38.4 m)(23.2 m)(11.2 m)(15.7 m)

EBIT margin, %

(10%)(24%)(26%)(31%)(24%)(91%)(46%)(22%)(37%)

Interest expense

(1.4 m)(1.4 m)(1.5 m)(1.5 m)(1.5 m)(3.8 m)(3.8 m)(4.1 m)(4.3 m)

Interest income

67 k63 k45 k37 k34 k62 k48 k58 k44 k

Income tax expense

80 k346 k(92 k)(61 k)(22 k)(103 k)(443 k)(174 k)(154 k)

Net Income

(9 m)(13.9 m)(11.2 m)(13 m)(10.9 m)(47.7 m)(66.8 m)(15.2 m)(21.3 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

95.2 m26.8 m124.6 m26.1 m

Accounts Receivable

310 k498 k375 k1.8 m

Inventories

19.6 m31.3 m27.9 m41.2 m

Current Assets

173.6 m147.8 m237.5 m129.8 m

PP&E

7.3 m25.7 m23.4 m23.3 m

Goodwill

29.1 m28.9 m28.7 m120.7 m

Total Assets

256.2 m248.2 m335.8 m359.7 m

Accounts Payable

6.3 m11 m17.5 m13.2 m

Current Liabilities

67.3 m29.6 m50.9 m44.9 m

Total Liabilities

246.9 m

Additional Paid-in Capital

321.8 m372.6 m404.5 m567.8 m

Retained Earnings

(216.1 m)(248.5 m)(298.9 m)(453.6 m)

Total Equity

103.3 m112.8 m

Financial Leverage

3.3 x3.2 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

31.8 m27.5 m20.2 m36.3 m35.4 m39.8 m31.4 m22 m15.5 m

Accounts Receivable

910 k878 k448 k121 k304 k2.6 m825 k659 k952 k

Inventories

28.5 m27.7 m35.1 m30.6 m33.4 m43.3 m42.1 m43.4 m42.7 m

Current Assets

170.7 m158.4 m138.4 m133 m132.3 m172.3 m155.3 m148.5 m113 m

PP&E

17.4 m23.1 m25.3 m24.8 m23.9 m25.9 m24.8 m24.2 m22.3 m

Goodwill

29.1 m28.9 m28.7 m28.7 m28.7 m93.7 m120.7 m120.9 m120.7 m

Total Assets

263.5 m256.3 m237.8 m231.3 m229.2 m407.1 m388.2 m380.7 m340.9 m

Accounts Payable

11.5 m10.8 m11.1 m11.8 m13.8 m15.7 m13.8 m13 m9.6 m

Current Liabilities

28.6 m29.3 m27.4 m28.2 m33 m59.6 m59 m60.1 m40.4 m

Additional Paid-in Capital

366.4 m368.7 m376.5 m381.5 m384.2 m484.1 m559.5 m563.1 m570.9 m

Retained Earnings

(219.8 m)(233.7 m)(259.7 m)(272.7 m)(283.6 m)(346.6 m)(413.4 m)(428.7 m)(474.9 m)

Total Equity

106.9 m99.1 m135.2 m144.7 m133.2 m94.9 m

Financial Leverage

2.2 x2.3 x3 x2.7 x2.9 x3.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(32.4 m)(50.4 m)(154.7 m)

Depreciation and Amortization

3.3 m5.9 m9.1 m

Inventories

(12 m)3.5 m3.5 m

Accounts Payable

2.7 m8.3 m(5.2 m)

Cash From Operating Activities

50 m(26.3 m)(31.1 m)(74.8 m)

Purchases of PP&E

(13.5 m)(4.2 m)(2.8 m)

Cash From Investing Activities

(43.3 m)2.9 m(28.5 m)

Cash From Financing Activities

2.1 m126.7 m5.3 m

Interest Paid

2 m2 m6.3 m

Income Taxes Paid

258 k124 k208 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(9 m)(13.9 m)(11.2 m)(13 m)(10.9 m)(47.7 m)(66.8 m)(15.2 m)(21.3 m)

Accounts Receivable

910 k878 k448 k121 k304 k2.6 m825 k659 k952 k

Inventories

28.5 m27.7 m35.1 m30.6 m33.4 m43.3 m42.1 m43.4 m42.7 m

Accounts Payable

11.5 m10.8 m11.1 m11.8 m13.8 m15.7 m13.8 m13 m9.6 m
USDY, 2017

Revenue/Employee

54.5 k

Financial Leverage

3.6 x

Endologix Market Value History

Market Position of Endologix

Competitors

Moderna Therapeutics
Health - Private
AmpliPhi Biosciences
Health - Public
CTD Holdings
Health - Public
Vital Therapies
Health - Public
Compare competitors

Traffic Overview of Endologix

Endologix Online and Social Media Presence

Endologix Company Life and Culture

You may also be interested in